Lipigon Pharmaceuticals AB

What does it take to bring your idea through early development and into clinical Phase II? Yesterday was the Lipigon Pharmaceuticals AB day! 14 year’s ago we founded the company to hold our IP from the academic research we were doing at Umeå universitet. It’s been some ups and downs but we have taken one of our assets -Lipisense®️into clinical Phase II trials. Today the remaining original founders meet up for lunch and then brought some cake to the lab. We talked about what it takes to reach this far. Many have contributed to this journey but to mention a few I would have to start with Gunilla, of course; great mentor, leader and a role model for how to be a good human being. Mikael Elofsson, a dear friend and for many years part of the Lipigon board. He is still involved as senior consultant. Investors such as Partnerinvest Norr (Mattias Eriksson), Fort Knox Förvaring AB (Martin Gunhaga and Markus Olsson), Antaros Medical (Lars Johansson and Johannes Hulthe) and Jonas Nilsson have been extremely important for our journey through the “biotech valley of death” and later on Sciety, G&W Fondkommission, Stockholm Corporate Finance and Corpura Fondkommission AB, who brought angels and retail investors on board. Thank you all for the support! Other important contributions have been made by Kurt Strömgren, who gave me the first financial innovation support already when I was a student. The innovation system with Umeå Biotech Incubator played a substantial role too. Especially Helén Fält did a great job helping us! Lars Ohman with whom I’ve been working with since 2012 and for some time we were hitting if of with more than 1 deal per year. The AstraZeneca collaborations 2014/2016-2018 being two major achievements. Later collaborations with Secarna Pharmaceuticals, HitGen Inc. (Jin Li) CombiGene and Leaderna (Jinqiao Wan) have also helped propell our company. Other important people that have contributed to where we are today are our current CDO Stefan Pierrou and the many consultants that we worked with throughout the years. To mention a few Erik Lund, Tom Schlossman and Anders Bergman. Companies that have supported us with specific distinction are the geneticists at 5 Prime Sciences (Brent Richards), the law firm Schjødt (Emil Hedberg and Adam Sirsjö) and the “all in one shop” drug development consultants at SDS Life Science - a Cytel company. Other importnat people who contributed, not claiming to mentioning everyone (sorry, I ran out of names!); Aivar Lõokene, Per-Anders Enquist and Valeria Saar-Kovrov, PhD. Current lab mentioned below, past and present board members not forgotten. So, as you see, it takes a lot of people - a great Team with a great variety of specialties, to bring an idea through early develpment and into clinical trials. Thinking of this is a good way to stay humble regarding your own achievements. There’s no “I” in Team, but there is a me, that sometimes needs this reminder.

Lipigon Pharmaceuticals AB congratulates Jinqiao Wan and his Leaderna team! ”We are very excited that our commercial partner is making swift advances in the clinical development of Lipisense®. The Phase 1 study is the initial step in the development program that ultimately aims to make our innovative drug candidate available on the Chinese market. We look forward to taking part of the study results and continuing our collaboration with Leaderna in the development of Lipisense®.” says Stefan K. Nilsson

Collaboration between Lipigon scientists and Leiden University Medical Center is now in print!

Interesting and instructive site visit for Lipigon Pharmaceuticals AB at APL (Apotek Produktion & Laboratorier AB) Umeå together with Västerbottens Handelskammare. Picture 1 Erik Haeffler presenting APL operations. Picture 2 Urban Hadarsson från Olofsfors, Lipigon head of clinical operations Isabelle Morin, and Ulf Söderlund from Enably Sävar AB.

Our CEO Stefan K. Nilsson flew to the US, first attending KERN LIPID CONFERENCE in Snowmass Village and later visiting Philip Gordts, PhD’s lab at UC San Diego.

Redeye AB-Intervju med VD Stefan K. Nilsson om samarbetet med Washington University i lungsjukdomar samt planerna framåt med Leaderna.

Team Lipigon Pharmaceuticals AB just won an overwhelming victory in the Umeå Biotech Incubator life science quiz. A whooping 26 out of 34 points with the second place far behind at 20. #dreamteam #allwedoiswin Benjamin Henriksson, Lars Bläckberg, Ingela Bergqvist and Elda Kutrolli

CEO Stefan K. Nilsson will be at LSX - partnering for Life Science eXecutives in London next week.

We’re looking forward welcoming you all to Sweden later this year.

Take the chance to meet our CEO Stefan K. Nilsson at this year’s BIO Spring.